Current status of anti-obesity medications and performance, an EHR based survey

Xiaoyang Ruan PhD [1], Rui Li MS [1], Liwei Wang MD PhD [2], Shuyu Lu MS [1], Andrew Wen MS [1], Murali Sameer MD [3], Hongfang Liu PhD [1,*]

[1] Department of health data science and AI, McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston

[2] Department of Clinical and Health Informatics, McWilliams School of Biomedical Informatics, University of Texas Health Science Center at Houston

[3] Department of Surgery, McGovern Medical School, University of Texas Health Science Center at Houston

* Corresponding author: Hongfang Liu, PhD

Postal address: 7000 Fannin Street #Suite 600, Houston, TX 77030

E-mail: hongfang.liu@uth.tmc.edu

Telephone: 713-500-3900

Background: Over the past two decades, the Food and Drug Administration (FDA) has significantly increased the approval of anti-obesity medications (AOMs) for obesity management. Both FDA-approved AOMs (F-AOMs) and off-label AOMs (O-AOMs) have gained popularity and demonstrated promising results in randomized clinical trials (RCTs). However, their effectiveness in real-world settings remains less understood. In this study, we evaluated population-level responses to AOMs and individual variability under real-world conditions, leveraging electronic health records (EHRs) as the primary data source for a comprehensive analysis of obesity relevant metrics.

Methods: EHRs of patients with obesity or overweight diagnosis were retrieved from the University of Texas Physician (UT-Physician) and EPIC COSMOS database. F-AOMs and O-AOMs were analyzed for their effects on obesity relevant metrics including body weight, body mass index (BMI), blood pressure (BP), high-density lipoprotein (HDL), low-density lipoprotein (LDL), HbA1c, and triglyceride levels.

Results: From the UT-Physician (U) and COSMOS (C) datasets, we identified 444K (2005–2023) and 30M (2018–2023) patients as obese or overweight, respectively. Of these, 72,089 (6.2%) and 10M (~30%) had exposure to AOMs. During the study period, [U:37%; C:48%] of patients underwent more than one treatment session. The median exposure time to F-AOMs are [U:2.9; C:6.1] months. The median exposure time to O-AOMs are [U:2.9; C:14] months. For both cohorts, F-AOMs generally showed

superior weight loss effects than O-AOMs. Tirzepatide and semaglutide were the most effective F-AOMs. Tirzepatide achieved 5% and 10% weight loss respectively in [U:65%; C:63%] and [U:33%; C:42%] of patients on long-term [U:76 wks; C:79 wks] exposure. Semaglutide achieved 5% and 10% weight loss respectively in [U:37%; C:45%] and [U:16%; C:25%] of patients on long-term [U:94 wks; C:88 wks] exposure. Both medications also benefited HDL, LDL, triglyceride, and HbA1c levels. Among O-AOMs, metformin demonstrated the most effective long-term [U:143 wks; C:166 wks] results, with [U:27%; C:32%] and [U:9%; C:14%] of patients achieving 5% and 10% weight loss, respectively. Significant individual variability in response was observed across all AOMs, irrespective of diagnosis type or exposure duration. Weight gain was noted in a subset of patients, ranging from [U:15%; C:18%] for tirzepatide (long-term) to [U:59%; C:62%] for lisdexamfetamine (long-term). Significant weight regain was consistently observed in both cohorts after discontinuing phentermine series, zonisamide, topiramate, and lisdexamfetamine.

Conclusions: Remarkable differences were observed between real-world evidence from EHR data and RCT reports on AOM effectiveness, highlighting the challenges of applying RCT results to diverse populations in routine practice. The wide variation in individual responses to both FDA-approved and off-label AOMs underscores the importance of personalizing obesity treatment to improve effectiveness, support long-term adherence, and promote sustainable care strategies.

Introduction

Obesity is a multifactorial disease that affects over a third of the world's population [1,2] , and ~34% of adults and 15–20% of children/adolescents in the USA [3]. Over 85% of adults are projected to be overweight or obese by 2030 in the USA [4]. Obesity greatly increases the risk of a wide spectrum of chronic disease such as type 2 diabetes, dyslipidemia, hypertension, cardiovascular disease, cancers, mortality [5], and causes significant social economic burden [6,7]. Obesity arises from a complex interplay of genetic [8,9,10,11] , epigenetic [12,13,14,15], non-genetic factors [16,17] , and genetic-environment interactions [18,19]. They together cause energy imbalance, excessive fat deposition, and obesity phenotype.[12]

During the past decades, a wide variety of therapies have emerged for obesity treatment, such as bariatric surgeries (BSs), anti-obesity medicines (AOMs), hydrogels, vagal nerve blockade, along with traditional dietary control and exercise. However, no single or combination of therapies perform consistently across individual patients, either in short or long term. For example, meta-analysis indicates BS patients have wide interindividual response during longer-term follow-up [20,21]. A prospective study of 6000 Roux-en-Y gastric bypass patients showed 17.1% with inadequate weight loss 1 year after surgery, and 23.1% as non-responders 5 years after surgery [22]. On the other hand, the majority of AOMs reduce average body weight by less than 10% at tolerable doses, with remarkably wide interindividual variability [23]. To illustrate, in Orlistat phase 3 trial [24], 27% and 59% participants failed to achieve >5% and >10% weight loss target in 1 year. In Phentermine phase 3 trial [25], 30% and 52% participants in the high dosage (15mg) intervention group failed to achieve >5% and 10% weight loss targets in 1 year. While GLP1 drug Semaglutide claims to achieve an average of >10% weight loss [26], this level of performance is seen in 69% of 1306 participants [27]. Even with additional intensive behavioral therapy, 10% weight loss is achieved in <75% participants [27]. The latestly approved GLP1 drug Tirzepatide [28] achieved >10% weight loss in only 69% participants at a relatively safe dosage level (5mg).

Notably, most of the weight loss performance results come from randomized clinical trials (RCTs), which have rigorous exclusion criteria (e.g. comorbidities), study regulations, and limited study duration [29]. Because of this, the outcomes are not consistently replicated in real-world settings. Whereas a recent study based on Electronic Health Record (EHR) [30] also implemented strict inclusion criteria (e.g. patients in weight management programs with nutritional, behavioral, and psychological guidelines, and two face-to-face visits in at least 3 months of follow-up), which resulted in a very limited cohort size. In view of the shortcomings, here we conducted a comprehensive walk through of the UT-Physician EHR systems on patients' exposures and responses to various AOMs, and validated some of the findings in a nationwide large cohort curated from the EPIC COSMOS database. We aim to provide a landscape view of the prevalence and effectiveness of AOMs in the general population, along with the complexity of treatment journey experienced by obesity patients. Specifically, we take a peek into the heterogeneous performance of AOMs within patients with similar demographic settings and same category of obesity diagnosis (e.g. local adiposity), and highlight the desiderata of next generation phenotyping for precision medicine.

Material and Methods
EHR databases and study cohorts
UT-Physician cohort
The UT-Physician cohort includes a total of 456,890 patients with either obesity diagnosis (n=217,040) or overweight with comorbidities (n=239,850) from 2005/01/01 to 2023/12/31 in the UT Health EHR system. The system was served by Allscripts before 2020, and then switched to EPIC. All records were mapped to the OMOP common data model [31] before further analysis. For obesity we considered diagnosis types including obesity, morbid obesity, localized adiposity, extreme obesity (with alveolar hypoventilation), drug-induced obesity, simple obesity based on corresponding OMOP concept code (Supp Text 1). For overweight we considered patients with any comorbidities (Supp Text 2) within 1 year prior to a BMI measurement ≥ 27. After excluding those with obesity-related surgery and without demographic information, finally 444,219 (97.2%) patients were left, among which 72,089 (6.2%) were exposed to at least one AOM. The sample processing flow is shown in Figure 1a. The University of Texas Institutional Review Board (IRB) approved the study, and the Ethics Committee waived the need for written informed consent from participants.

COSMOS cohort
COSMOS is a platform enabling users to leverage de-identified data from over 277 million patients (as of November 2024) from more than 250 health systems across the United States and Lebanon to advance human health through research and clinical integration. COSMOS EHR is based on caboodle data model of EPIC data warehouse. For the COSMOS cohort, we selected 29,793,115 patients with ICD-9 and ICD-10 based obesity diagnosis (Supp Text 3) from 2018/01/01 to 2023/12/31. We further excluded those with any obesity-related surgeries (Supp Text 4), and 29,075,858 (97.6%) patients left. Among which 10,794,237 (37%) were exposed to at least one AOM. Due to limited computation capacity, we randomly selected 1,002,225 (~10%) patients for downstream analysis. The sample processing flow is shown in Figure 1b.

[Insert Figure 1 Here]

FDA approved AOMs (F-AOMs) and Off-Label AOMs (O-AOMs)
For F-AOMs, we considered bupropion naltrexone, orlistat, phentermine, phentermine topiramate, liraglutide, semaglutide, tirzepatide that were approved by FDA for obesity treatment. For O-AOMs we considered bupropion, canagliflozin, dapagliflozin w/wo saxagliptin, empagliflozin w/wo linagliptin, lisdexamfetamine, metformin w/wo (liflozin, liptin, litazone, statin), topiramate, zonisamide. Specifically, exposure to an O-AOM ingredient for less than 30 days without a neighboring (30 days before or after) record was removed to allow for occasional use of O-AOMs for other purposes. While most of the O-AOMs are for diabetes treatment, we make no explicit distinction between the treatment purposes when the treatment course is longer than 30 days, in which case an impact on body weight should be anticipated. For the UT-Physician cohort, we searched the RxNav database [32] for all aliases of each drug ingredient and then searched the OHDSI Athena [33] database for concept ids of the original ingredient and all aliases. The concept ids were combined to represent a single corresponding ingredient. For

COSMOS data, AOM usage records were identified by regular expression match of drug ingredient names.

Drug exposure end date
While the start date for AOM exposure is always explicitly provided, the end date is not consistently available due to refills. In this study, the exposure end date is formulated as: exposure start date + (days supply * (refills + 1)). For records without refill information, refills are set to 0. The days supply is either directly provided or calculated using the equation: provided exposure end date - provided exposure start date + 1.

Treatment session
To effectively manage the complexity of AOM treatment in real-world scenarios, we meticulously designed algorithms to define a treatment session. This approach captures a continuous period during which the patient is exposed to generally the same active ingredient(s). Specifically, compare to an existing exposure record REC_A, a new exposure record REC_B belongs to the same treatment session (as REC_A) if it 1) has exactly the same ingredient(s) as REC_A and there is ≤40 days gap between start of REC_B and end of REC_A, or 2) has less ingredient than REC_A, and has both exposure length and gap to REC_A ≤40 days, or 3) has new ingredient(s) added within 40 days of initiating REC_A and has exposure length ≤40 days. For all other circumstances, we consider REC_B as a new treatment session.

Measurements
We retrieved measurements for body weight, body mass index (BMI), high-density lipoprotein (HDL), low-density lipoprotein (LDL), total cholesterol (TC), triglycerides, systolic blood pressure (SBP), diastolic blood pressure (DBP), and HbA1C level throughout each patient's EHR history. Specifically, as a form of cross-validation, body weight and BMI were treated independently, with each metric retrieved separately rather than inferred from one another. If a measurement has several values on a single day, the median value is used if the largest value is less than 20% higher than the minimum value or otherwise set to unavailable. For each treatment session, the ideal scenario is measurements are available on exactly both the start and end dates, which however is not always possible. To compensate for this, we consider four scenarios (Supp Table 3). Each treatment session belongs exclusively to one scenario with precedence decreasing from scenario 1 to 4. For each scenario we enforce a minimum of 30 days difference between two measurements to allow for meaningful treatment effect. Furthermore, with slight modification to previous report [34], we have adopted the equation (90 * exposure days / 365 days) to calculate a customized allowable flanking range for different lengths of drug exposures. The calculated value is hard-clamped to a range between 30 days and 180 days to avoid overly stringent or loose requirements. Specifically, a measurement is considered invalid if there are other AOM exposures between the measurement date and the date of exposure to the AOM of interest.

Calculation of weight change after AOM discontinuation
For each exposure record, the reference weight was determined by using the median body weight recorded from 30 days before to 30 days after the exposure end date. This reference weight was then compared with the median weights from six non-overlapping

periods—30 to 90 days, 91 to 180 days, 181 days to 1 year, 1 to 1.5 years, 1.5 to 2 years, and over 2 years—to calculate the percentage changes in weight. Additionally, for a weight measurement after exposure to be considered valid, there should be no exposure to any AOMs from the end of the exposure period until the weight measurement is taken.

Statistical analysis
Continuous data are summarized as medians and interquartile ranges (IQR). Categorical data are presented as frequencies and percentages. For percentage changes of measurements before and after treatment, the values beyond outer fence (Q3 + 3*IQR, Q1 − 3*IQR) were removed.

Results
Baseline characteristics of the study cohorts
The baseline characteristics of the two study cohorts, including those exposed to AOMs, are shown in Table 1. The percentages of AOM exposure are 6.2% and 37% for the UT-Physician and COSMOS cohorts, respectively, primarily reflecting the increasing popularity of AOMs after around 2020 (Supp Figure 1 and 2).

[Insert Table 1 here]

AOMs exposure in the UT-Physician cohort
From 2005 to 2023, the most commonly used F-AOMs are semaglutide, phentermine, liraglutide, and tirzepatide, having patient exposure rates of 10%, 5%, 3.4%, and 1.9% respectively (Supp Figure 4). In contrast, the leading O-AOMs are metformin, bupropion, and topiramate, with exposure rates of 59%, 14%, and 6.4%, respectively (Supp Figure 4). Across all AOMs, short-term exposure, defined as 112 days or less, represents the predominant type (Supp Figure 3).

F-AOMs exposure was rare before 2015. From 2015 to 2020, the F-AOMs were dominated by liraglutide, phentermine, and bupropion naltrexone (Supp Figure 1). Significant rise in exposure to both F-AOMs and O-AOMs was observed after 2020, mainly attributable to semaglutide (Supp Figure 1) and metformin series (Supp Figure 2). A sharp decrease in semaglutide exposure was observed around 2023, mainly due to a drop in insurance coverage for weight management. A notable rise in tirzepatide was observed after 2022, and became the dominating F-AOMs at the end of 2023.

For patients with AOM exposure, 69% had exposure to a single AOM, 20% to two AOMs, and 11% to three or more AOMs. Notably, there were three patients who were exposed to ten or more AOMs. Regarding F-AOMs, 73% of patients were exposed to just one F-AOM, 22% to two F-AOMs, and a smaller proportion of 5% experienced three or more F-AOMs.

Number and length of treatment sessions
We use treatment session to denote a period with continuous exposure to certain drug ingredient(s). The switch to a new treatment session involves physical, economical, as well as psychological burdens to the patient, and usually results from a failure or less

ideal effect of the previous session. Overall, [U:63%; C:52%] of patients experienced only one treatment session during the inspected time frame. The rest of [U:37%; C:48%] patients experienced two or more treatment sessions (A maximum of 20 treatment sessions for one patient with 10 years of treatment effort). Subgroup analyses in the UT-Physician cohort show no remarkable differences across diagnosis types except for overweight, which has slightly more patients (69%) experienced a single treatment session (Figure 2). The median treatment session lengths are [U:2.9; C:6.1] months for all F-AOMs, [U:3.2: C:6.2] months for semaglutide, and [U:3.5; C:4.1] months for tirzepatide. The median treatment session lengths for O-AOMs are [U:2.9; C:14] months.

[Insert Figure 2 here]

Responses of obesity relevant metrics to AOMs

For both cohorts, we investigated the effect of short to long term exposure (short-term: 30 to 112 days; median-term: 113 to 365 days; long-term: >365 days) [34] to F-AOMs (Figure 3) and O-AOMs (Supp Figure 5). The metrics that are relevant to obesity, including body weight, BMI, HDL, LDL, SBP, DBP, HbA1c, and triglyceride levels were analyzed on their percentage changes before and after AOM exposure. In the following report, we employ both visual judgment of distributions and statistical significance tests to 1) prevent overlooking large effect sizes in exposures with small sample sizes, and 2) avoid misinterpreting high statistical significance purely due to large sample sizes but with less meaningful effect sizes.We summarize the major observations as follows.

Response to F-AOMs (Figure 3)
Body weight and BMI
Both short and long-term exposure to tirzepatide and semaglutide demonstrated a significant reduction in body weight and BMI, achieving statistical significance at the $p<0.001$ level with a visually discernible effect size in both cohorts. Phentermine shows moderate reduction effect with short or medium-term exposure, but consistently lacks significance in long-term exposure for both cohorts. We observed no clear benefit of phentermine/topiramate combination over phentermine alone, both perform similarly across all exposure lengths. Liraglutide shows only a mild reduction effect in the long-term exposure groups of both cohorts. Orlistat has almost no visually discernible effect across all exposure lengths.

Lipid levels
Both tirzepatide and semaglutide demonstrate either significant or visually discernible benefits (i.e., reduction) in LDL and triglyceride levels across all exposure lengths in both cohorts. However, their benefits (i.e., increase) on HDL levels are limited to medium and long-term exposures. In contrast, the effects of other F-AOMs on HDL and LDL levels are generally inconsistent across the two cohorts. All F-AOMs show some benefit (i.e., reduction) in triglyceride levels. However, the effects of phentermine (w/wo topiramate) and orlistat tend to diminish with long-term exposure in both cohorts.

Blood pressure and HbA1c levels

In both cohorts, tirzepatide and semaglutide significantly reduce HbA1c levels, regardless of exposure length. They also show mild effects in lowering both SBP and DBP, with generally larger effect size on longer exposure. Liraglutide shows a mild effect in reducing HbA1c levels, with no clear effect on blood pressure. The other F-AOMs generally show no noticeable impact on blood pressure or HbA1c levels, except that long-term exposure to phentermine (w/wo topiramate) and orlistat slightly increases SBP in the COSMOS cohort.

[Insert Figure 3 here]

Response to O-AOMs (Supp Figure 5)
Body weight and BMI
Among O-AOMs, medium to long-term exposure to metformin series and SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) in both cohorts mildly reduce body weight and BMI, though with a much smaller effect size than tirzepatide and semaglutide. Most other O-AOMs generally did not demonstrate benefits for body weight or BMI in either cohort. Notably, long-term exposure to lisdexamfetamine consistently increases body weight and BMI across both cohorts.

Lipid levels
Only metformin and empagliflozin consistently show a mild reduction in LDL in both cohorts. The benefits (i.e., increase) of all O-AOMs on HDL, if any, are elusive and marginal. The majority of O-AOMs reduce triglycerides, with a notably larger effect size on short-term exposure than medium to long-term exposure.

Blood pressure and HbA1c levels
No O-AOM has a significant impact on either SBP or DBP. Overall, the metformin series and SGLT2 inhibitors are more effective than other O-AOMs in lowering HbA1c levels, although their effect size is considerably smaller than that of F-AOMs.

Variations in body weight responses to AOMs
While certain AOMs significantly reduce body weight at the population level, individual responses vary widely. For instance, while long-term exposure to metformin shows a median [U:1.6%; C:1.9%] body weight reduction (p≤0.001) (Supp Figure 5), [U:38%; C:39%] of cases experienced weight gain, and [U:73%; C:68%] fail to achieve 5% weight loss (Supp Table 1 and 2). Long-term exposure to tirzepatide, the most effective F-AOM, shows a median [U:7.4%; C:8.1%] body weight reduction (Figure 3). Here, [U:33%; C:42%] of cases achieve a weight loss of 10% or more, but [U:35%; C:37%] failed to achieve 5% weight loss, and [U:15%; C:18%] experienced weight gain at the end of exposure (Table 2). As a comparison, [U:32%; C:30%] cases experienced weight gain after long-term exposure to semaglutide (Table 2). Among F-AOMs, orlistat and bupropion naltrexone lead to weight gain in ≥50% cases (Table 2). Among O-AOMs, lisdexamfetamine and zonisamide have the worst performance, both resulting in weight gain in ≥50% cases across both cohorts on all exposure lengths (Supp Table 1 and 2).

Scatterplots of individual records of F-AOM exposure from the UT-Physician cohort indicate that, aside from tirzepatide and semaglutide, there is typically no apparent

correlation between the duration of exposure and body weight change at the group level (Figure 4). With semaglutide, longer exposure is associated with increased weight loss up to 1.5 years, beyond which no further benefits are noted at the group level. For tirzepatide, the most rapid weight loss occurs within the 1st year of exposure. Beyond one year, the effects on weight loss are more pronounced in overweight patients. Overall, the weight loss effect varies remarkably across individuals for all F-AOMs, regardless of the duration of exposure. In additional analyses, similar levels of interindividual variations were observed in all gender, race, diagnosis type, and age at exposure subgroups (data not shown).

[Insert Figure 4 here]

Weight changes after AOMs discontinuation
We analyzed body weight changes across six distinct, non-overlapping periods after discontinuing F-AOMs (Figure 5) and O-AOMs (Supp Figure 6). Individual responses to AOM discontinuation varied widely, though certain patterns emerged. For F-AOMs, bupropion-naltrexone and phentermine (w/wo topiramate) exhibited a clear trend of gradual weight regain in both cohorts following discontinuation. In contrast, tirzepatide and semaglutide showed minor weight loss persisting up to two years post-discontinuation. For O-AOMs, stopping zonisamide, topiramate, and lisdexamfetamine was associated with substantial weight regain over time across both cohorts, whereas discontinuing metformin generally did not lead to significant weight change at group level.

[Insert Figure 5 here]

Discussion

With two data sources managed under different data models—the OMOP common data model and the COSMOS Caboodle data model—and patient cohorts characterized by highly diversified population demographics, we achieved notably consistent insights regarding patient responses to AOMs and changes in body weight after AOMs cessation. The shorter AOM exposure durations and slightly reduced weight loss effects observed in the UT-Physician cohort likely reflect the fragmented healthcare system and the significant diversity in social determinants of health within the Houston area. Overall, our findings highlight secondary use of EHR as a valuable and reliable strategy for retrospective verification of treatment responses in real-world scenarios, aligning with the increasing popularity of using EHR in RCTs [35] and to derive real-world evidence [36]. The consistency across data models underscores the potential of EHR to support comparative analyses and improve treatment evaluations across varied clinical questions [37].

Several F-AOMs showed significantly less weight loss effect compared to RCTs reports [23]. For instance, semaglutide achieved a 10% weight loss in at least 69% of participants after 68 weeks in a RCT [27], whereas our analysis indicated that up to 25% of patients reached this threshold after a median exposure of 88 weeks. Similarly, tirzepatide's effectiveness in our study (10% weight loss in [U:33%; C:42%] of patients after [U:76; C:79] weeks) fell short of RCT results, where 69% of patients lost at least 10% of their weight over 72 weeks [28]. However, it's worth noting that our findings align more closely with another RCT of tirzepatide involving obese patients with diabetes [38], where a 40-week treatment with 5 mg resulted in 47% of patients losing at least 5% body weight, similar to our [U:48%; C:50%] achieving this goal with an average of [U:39; C:38] weeks exposure.

The disparity can be explained as follows. Firstly, the dosages used in real-world clinical settings tend to be more conservative for some AOMs. For example, available data indicates that approximately 80% of semaglutide prescriptions are at or below 0.5mg weekly, starting from 0.25mg and gradually increasing to 0.5mg, which is significantly lower than the 2.4 mg weekly used in RCTs. Secondly, the rigorous inclusion/exclusion criteria of RCTs also play a crucial role. For example, our findings on tirzepatide align better with the trial involving diabetes patients [38] than the trial without diabetes [28], which may reflect the confounding effect of comorbidities observed in real-world settings. Indeed, in the UT-Physician cohort about half of the patients screened for overweight had at least one HbA1c measurement in the prediabetic range (5.7% to 6.5%), signifying the confounding effect of comorbidities in real-world practice. Thirdly, medication adherence in real-world practice is generally less strict than in RCTs. Adherence issues include non-fulfillment (never initiated), non-persistence (stop taking after initiation), non-conforming (skipping dose, incorrect does) [39] have been reported in various AOM adherence studies [40,41,42], and likely diminishes AOM effectiveness. Overall, our results reflect the general population's response to AOMs amidst these real-world factors.

Our findings of weight regain after discontinuation of several F-AOMs and O-AOMs were consistently observed in both cohorts and aligned with previous research.

Specifically, weight regain following the cessation of bupropion-naltrexone [43] and phentermine [34] (F-AOMs), as well as zonisamide [44] and topiramate [45] (O-AOMs), has been documented in earlier studies. In both cohorts, discontinuing lisdexamfetamine demonstrated remarkably significant weight regain, which however was not formally documented to the best of our knowledge. On the other hand, our analysis indicates that discontinuing tirzepatide or semaglutide does not lead to weight regain at population level, which contrasts with RCTs suggesting that stopping tirzepatide [46] or semaglutide [47] also leads to weight regain. These discrepancies may be explained by sample selection bias, differences in exposure length distributions, and variations in dosages. This also underscores the importance of further research to bridge the gap between RCT data and real-world evidence.

We noted substantial variations in individual responses to AOMs, regardless of the duration of exposure. For O-AOMs, variations could be due to the treatment not always being aimed at obesity management, so early response might not influence the decision to continue or discontinue the treatment. This could explain the fluctuations in body weight changes over short to long term exposures. On the other hand, we didn't specifically observe less variation in body weight responses to long-term F-AOMs, which are supposedly based on short-term effectiveness. This suggests that either some patients may not be adjusting their treatment plans promptly based on their early response, or a potential tolerance after long-term exposure.

The remarkable inconsistent responses at individual level to various AOMs align with recent move away from the oversimplified classification by BMI [48] toward more sophisticated staging strategies [49] and phenotyping-guided therapies [50]. Recent review articles [51,52] highlighted the necessity of obesity deep phenotyping for precision medicine, as "every obese individual should be assessed based on their own specific and unique circumstances" [53]. Our findings of highly varied individual response to various AOMs reinforce the clinical significance of phenotyping-guided therapies to optimize AOM administration.

Conclusion
Our study highlighted the gaps between clinical trials and real-world evidence derived from EHR data regarding the effectiveness of AOMs. These discrepancies point to the challenges of generalizing clinical trial findings to broader, more diverse populations encountered in routine practice. The observed substantial variability in individual responses to both FDA-approved and off-label AOMs further emphasizes the need for a personalized approach to obesity pharmacotherapy, which may not only enhance treatment efficacy but also improve long-term adherence, paving the way for more sustainable obesity care strategies.

Limitations

This study primarily examined the effectiveness of AOMs on obesity-related metrics, excluding an analysis of potential side effects, which will be addressed in a separate study. When stratified by specific medication, exposure duration, and type of measurement, the UT-Physician cohort presents a limited sample size, which may reduce its representativeness at the population level. The COSMOS database, encompassing all healthcare systems using the EPIC system, may contain overlapping patient records with the UT-Physician database, particularly following UT-Physician's transition to the EPIC system in 2020. However, as UT-Physician records from post-2020 represent less than 1% of those in COSMOS, the effect of this overlap on our findings should be minimal. Finally, due to limited computational resources on the COSMOS platform, we were only able to analyze the data from 2018 to 2023. This may cause a biased estimation of overall effectiveness of AOMs widely used before 2018.

Data availability

The data supporting this study are not publicly available due to restrictions related to patient privacy and confidentiality. Access to the data may be granted upon reasonable request and with appropriate institutional approvals.

Contributions

XR led the study design, conducted data analysis, and drafted the manuscript. RL carried out data analysis for the COSMOS cohort. LW and SL contributed to manuscript preparation. AW oversaw the harmonization of the UT-Physician EHR with the OMOP CDM. MS provided expert insights as an obesity clinician. HL contributed to the study design and coordinated the overall project.

Funding source

The study was funded by The University of Texas Health Science Center at Houston CPRIT RR230020

Figure 1 Sample processing flow for a) UT-Physician cohort, b) COSMOS cohort.

Figure 2 Distribution of treatment session counts in patients with different diagnoses in the UT-Physician cohort.

a

b

Figure 3 Distribution of percentage change in obesity relevant metrics after F-AOM exposure for a) UT-Physician cohort, and b) COSMOS cohort. Result displayed for each drug and category with a minimum of 20 observations. Black and red dots depict median value <0 and ≥0, respectively. Numbers on the right of each distribution shown as (number of observed records/number of unique patients). The asterisks on the left denote significance (p≤0.05 (*), p≤0.01 (**), and p≤0.001(***)) of two-tailed z-test against the null hypothesis of mean value 0.

Figure 4 Exposure duration to F-AOMs and changes in body weight in the UT-Physician cohort, categorized by type of diagnosis (all obesities vs overweight), with LOESS smooth lines applied using local regression.

Figure 5 Body weight percentage changes after discontinuing F-AOMs, using body weight at the end of exposure as reference weight. a) UT-Physician cohort. b) COSMOS cohort.

Table 1 Baseline characteristics of the study cohorts

	UT-Physician (2005-2023)			COSMOS (2018-2023)		
	Total Cohort	AOMs exposure	Exposure %	Total Cohort	AOMs exposure c	Exposure %
Count	444,219	72,089	6.20%	29,075,858	10,794,237	37%
Gender						
Male	178,097 (40%)	26,891 (37%)	15%	11,975,310 (42%)	3,951,186 (37%)	33%
Female	266,057 (60%)	45,188 (63%)	17%	17,095,675 (59%)	6,841,461 (63%)	40%
Race						
White	150,802 (34%)	30,425 (42%)	20%	20,640,986 (71%)	7,971,073 (74%)	39%
Black or AA	108,170 (24%)	17,501 (24%)	16%	5,286,724 (18%)	1,924,571 (18%)	36%
Asian	9,499 (2.1%)	1,896 (2.6%)	20%	606,726 (2.1%)	199,863 (1.9%)	33%
Others	1,758 (0.4%)	279 (0.4%)	16%	1,650,476 (5.6%)	500,238 (4.6%)	30%
Unknown	173,990 (39%)	21,988 (31%)	13%	890,946 (3.1%)	198,492 (1.8%)	22%
Age at first diagnosis a	51 (37, 63)	56 (42, 66)	-	48 (35, 64)	51 (40, 64)	-
Diagnosis category b						
Obesity	139,897 (31%)	20,544 (28%)	15%	16,431,230 (57%)	5,829,254 (54%)	35%
Morbid obesity	61,495 (14%)	12,399 (17%)	20%	7,677,677 (26%)	3,669,632 (34%)	48%
Localized adiposity	1,738 (0.4%)	288 (0.4%)	17%	299,290 (1.0%)	104,714 (1.0%)	35%
Extreme obesity	1,032 (0.2%)	136 (0.2%)	13%	112,120 (0.4%)	48,297 (0.5%)	43%
Drug-induced obesity	456 (0.1%)	141 (0.2%)	31%	59,888 (0.2%)	28,310 (0.3%)	47%
Overweight	239,600 (54%)	38,581 (54%)	16%	4,495,653 (16%)	1,114,030 (10%)	25%

a Values shown as median(1st quartile, 3rd quartile)

b For patients with multiple different obesity diagnoses, the first diagnosis is used. Simple obesity merged into obesity

c 1/10 of the patients were randomly selected for final analysis

Table 2 Response of body weight to F-AOMs

Ingredient	Exposure Term	UT-Physician					COSMOS				
		Exposure Length (wks)	Records/Patients	≥10% loss	≥5% loss	Weight gain	Exposure Length (wks)	Records/Patients	≥10% loss	≥5% loss	Weight gain
bupropion naltrexone	Short	9[4,10] [a]	100/98	3(3%)	12(12%)	34(34%)	11[6,16]	3633/3446	39(1%)	283(8%)	1618(45%)
	Medium	20[18,23]	29/29	0(0%)	5(17%)	13(45%)	35[26,42]	3936/3690	244(6%)	737(19%)	1882(48%)
	Long	- [b]	0/0	-	-	-	107[74,130]	3616/3418	399(11%)	867(24%)	1908(53%)
liraglutide	Short	13[8,14]	485/458	5(1%)	42(9%)	208(43%)	11[6,17]	8676/8276	176(2%)	966(11%)	3664(42%)
	Medium	26[24,37]	345/330	10(3%)	52(15%)	168(49%)	36[26,43]	10414/9925	768(7%)	2261(22%)	4634(44%)
	Long	89[69,112]	54/53	5(9%)	10(19%)	23(43%)	113[78,137]	11203/10843	1657(15%)	3333(30%)	4988(45%)
orlistat	Short	12[8,10]	27/26	0(0%)	2(7%)	13(48%)	11[6,16]	437/418	<11(NaN%) [c]	33(8%)	196(45%)
	Medium	45[26,49]	29/29	1(3%)	2(7%)	19(66%)	37[26,44]	510/489	19(4%)	83(16%)	252(49%)
	Long	-	10/10	-	-	-	113[79,138]	496/489	49(10%)	116(23%)	249(50%)
phentermine	Short	11[7,15]	781/706	18(2%)	122(16%)	294(38%)	13[8,19]	22424/20256	992(4%)	5133(23%)	6244(28%)
	Medium	34[25,41]	597/553	49(8%)	157(26%)	238(40%)	36[26,42]	26065/24050	3320(13%)	8366(32%)	9424(36%)
	Long	90[68,114]	292/286	32(11%)	72(25%)	140(48%)	106[75,130]	23836/22834	2993(13%)	6500(27%)	11729(49%)
phentermine topiramate	Short	10[8,12]	39/37	0(0%)	4(10%)	11(28%)	12[7,17]	7126/6461	228(3%)	1300(18%)	2333(33%)
	Medium	26[25,26]	26/26	1(4%)	3(12%)	12(46%)	36[26,40]	7864/7236	1020(13%)	2462(31%)	2999(38%)
	Long	-	0/0	-	-	-	99[72,121]	5883/5624	896(15%)	1733(29%)	2853(48%)
semaglutide	Short	11[6,17]	1711/1590	30(2%)	230(13%)	623(36%)	13[7,19]	30574/29375	696(2%)	4060(13%)	11554(38%)
	Medium	38[26,49]	1699/1628	180(11%)	531(31%)	500(29%)	42[30,45]	41446/40257	6108(15%)	13936(34%)	13750(33%)
	Long	94[70,117]	721/718	114(16%)	266(37%)	232(32%)	88[71,102]	25105/24872	6332(25%)	11232(45%)	7419(30%)
tirzepatide	Short	13[8,19]	366/346	15(4%)	106(29%)	99(27%)	15[8,18]	9583/9384	478(5%)	2167(23%)	2979(31%)
	Medium	39[27,54]	300/295	58(19%)	143(48%)	69(23%)	38[29,42]	8340/8175	2286(27%)	4163(50%)	1940(23%)
	Long	76[64,103]	54/54	18(33%)	35(65%)	8(15%)	79[68,79]	2417/2417	1025(42%)	1528(63%)	426(18%)

[a] Value shown as median[IQR]

[b] Statistics only calculated for 20 or more observed records

[c] Records with count ≤10 masked per COSMOS policy

References

1. Ng, M. *et al.* Global, regional, and national prevalence of overweight and obesity in children and adults during 1980-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet* **384**, 766–781 (2014).

2. Stevens, G. A. *et al.* National, regional, and global trends in adult overweight and obesity prevalences. *Popul. Health Metr.* **10**, 22 (2012).

3. Mitchell, N. S., Catenacci, V. A., Wyatt, H. R. & Hill, J. O. Obesity: overview of an epidemic. *Psychiatr. Clin. North Am.* **34**, 717–732 (2011).

4. Wang, Y., Beydoun, M. A., Liang, L., Caballero, B. & Kumanyika, S. K. Will all Americans become overweight or obese? estimating the progression and cost of the US obesity epidemic. *Obesity* **16**, 2323–2330 (2008).

5. *Obesity Epidemiology.* (Oxford University Press, 2008).

6. Su, W. *et al.* Modeling the clinical and economic implications of obesity using microsimulation. *J. Med. Econ.* **18**, 886–897 (2015).

7. Kim, D. D. & Basu, A. Estimating the Medical Care Costs of Obesity in the United States: Systematic Review, Meta-Analysis, and Empirical Analysis. *Value Health* **19**, 602–613 (2016).

8. Stunkard, A. J., Foch, T. T. & Hrubec, Z. A twin study of human obesity. *JAMA* **256**, 51–54 (1986).

9. Stunkard, A. J. *et al.* An adoption study of human obesity. *N. Engl. J. Med.* **314**, 193–198 (1986).

10. Maes, H. H., Neale, M. C. & Eaves, L. J. Genetic and environmental factors in relative body weight and human adiposity. *Behav. Genet.* **27**, 325–351 (1997).

11. Paolacci, S. *et al.* Mendelian non-syndromic obesity. *Acta Biomed.* **90**, 87–89 (2019).

12. Barres, R. *et al.* Weight loss after gastric bypass surgery in human obesity remodels promoter methylation. *Cell Rep.* **3**, 1020–1027 (2013).

13. Keller, M. *et al.* Genome-wide DNA promoter methylation and transcriptome analysis in human adipose tissue unravels novel candidate genes for obesity. *Mol Metab* **6**, 86–100 (2017).

14. Nilsson, E. *et al.* Altered DNA methylation and differential expression of genes influencing metabolism and inflammation in adipose tissue from subjects with type 2 diabetes. *Diabetes* **63**, 2962–2976 (2014).

15. Wahl, S. *et al.* Epigenome-wide association study of body mass index, and the adverse outcomes of adiposity. *Nature* **541**, 81–86 (2017).

16. World Health Organization. *Obesity: Preventing and Managing the Global Epidemic; Report of a WHO Consultation on Obesity.* (1998).

17. World Health Organization. *Obesity: Preventing and Managing the Global Epidemic : Report of a WHO Consultation.* (World Health Organization, 2000).

18. Ravussin, E. & Bogardus, C. Energy balance and weight regulation: genetics versus environment. *Br. J. Nutr.* **83 Suppl 1**, S17–20 (2000).

19. Bouchard, C. *et al.* The response to long-term overfeeding in identical twins. *N. Engl. J. Med.* **322**, 1477–1482 (1990).

20. Chang, S.-H. *et al.* The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. *JAMA Surg.* **149**, 275–287 (2014).

21. Courcoulas, A. P. *et al.* Seven-Year Weight Trajectories and Health Outcomes in the Longitudinal Assessment of Bariatric Surgery (LABS) Study. *JAMA Surg.* **153**, 427–434 (2018).

22. Brissman, M., Beamish, A. J., Olbers, T. & Marcus, C. Prevalence of insufficient weight loss 5 years after Roux-en-Y gastric bypass: metabolic consequences and prediction estimates: a prospective registry study. *BMJ Open* **11**, e046407 (2021).

23. Chakhtoura, M. *et al.* Pharmacotherapy of obesity: an update on the available medications and drugs under investigation. *eClinicalMedicine* **58**, (2023).

24. Torgerson, J. S., Hauptman, J., Boldrin, M. N. & Sjöström, L. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. *Diabetes Care* **27**, 155–161 (2004).

25. Gadde, K. M. *et al.* Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. *Lancet* **377**, 1341–1352 (2011).

26. Müller, T. D., Blüher, M., Tschöp, M. H. & DiMarchi, R. D. Anti-obesity drug discovery: advances and challenges. *Nat. Rev. Drug Discov.* **21**, 201–223 (2022).

27. Wilding, J. P. H. *et al.* Once-Weekly Semaglutide in Adults with Overweight or Obesity. *N. Engl. J. Med.* **384**, 989–1002 (2021).

28. Jastreboff, A. M. *et al.* Tirzepatide Once Weekly for the Treatment of Obesity. *N. Engl. J. Med.* **387**, 205–216 (2022).

29. Carey, T. A. & Stiles, W. B. Some Problems with Randomized Controlled Trials and Some Viable Alternatives. *Clin. Psychol. Psychother.* **23**, 87–95 (2016).

30. Calderon, G. *et al.* Effectiveness of anti-obesity medications approved for long-term use in a multidisciplinary weight management program: a multi-center clinical experience. *Int. J. Obes.* **46**, 555–563 (2022).

31. Hripcsak, G. *et al.* Observational Health Data Sciences and Informatics (OHDSI): Opportunities for Observational Researchers. *Stud Health Technol Inform* **216**, 574–578 (2015).

32. Zeng, K., Bodenreider, O., Kilbourne, J. & Nelson, S. RxNav: a web service for standard drug information. *AMIA Annu Symp Proc* **2006**, 1156 (2006).

33. Reich, C. *et al.* OHDSI Standardized Vocabularies—a large-scale centralized reference ontology for international data harmonization. *J. Am. Med. Inform. Assoc.* **31**, 583–590

(2024).

34. Lewis, K. H. *et al.* Safety and Effectiveness of Longer-Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort. *Obesity* **27**, 591–602 (2019).

35. Kalankesh, L. R. & Monaghesh, E. Utilization of EHRs for clinical trials: a systematic review. *BMC Med Res Methodol* **24**, 70 (2024).

36. Knevel, R. & Liao, K. P. From real-world electronic health record data to real-world results using artificial intelligence. *Annals of the Rheumatic Diseases* **82**, 306–311 (2023).

37. Strayer, N. *et al.* Interoperability of phenome-wide multimorbidity patterns: a comparative study of two large-scale EHR systems. *medRxiv* (2024) doi:10.1101/2024.03.28.24305045.

38. Frías, J. P. *et al.* Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. *N. Engl. J. Med.* **385**, 503–515 (2021).

39. Jimmy, B. & Jose, J. Patient medication adherence: measures in daily practice. *Oman Med. J.* **26**, 155–159 (2011).

40. Kan, H. *et al.* Real-world primary nonadherence to antiobesity medications. *Journal of Managed Care & Specialty Pharmacy* (2023) doi:10.18553/jmcp.2023.23083.

41. Gasoyan, H., Pfoh, E. R., Schulte, R., Le, P. & Rothberg, M. B. Early- and later-stage persistence with antiobesity medications: A retrospective cohort study. *Obesity* **32**, 486–493 (2024).

42. Ko, H.-J., Kim, J.-W. & Lim, S. Adherence to and Dropout from Liraglutide 3.0 mg Obesity Treatment in a Real-World Setting. *J Obes Metab Syndr* **31**, 254–262 (2022).

43. Kim, N. *et al.* Cost-effectiveness analysis of semaglutide 2.4 mg for the treatment of adult patients with overweight and obesity in the United States. *Journal of Managed Care & Specialty Pharmacy* (2022) doi:10.18553/jmcp.2022.28.7.740.

44. Shin, J. H., Gadde, K. M., Østbye, T. & Bray, G. A. Weight changes in obese adults 6-months after discontinuation of double-blind zonisamide or placebo treatment. *Diabetes Obes Metab* **16**, 766–768 (2014).

45. Verrotti, A. *et al.* Weight regain after discontinuation of topiramate treatment in patients with migraine: a prospective observational study. *CNS Drugs* **29**, 163–169 (2015).

46. Aronne, L. J. *et al.* Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. *JAMA* **331**, 38–48 (2024).

47. Wilding, J. P. H. *et al.* Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. *Diabetes Obes Metab* **24**, 1553–1564 (2022).

48. Garvey, W. T. & Mechanick, J. I. Proposal for a Scientifically Correct and Medically Actionable Disease Classification System (ICD) for Obesity. *Obesity* **28**, 484–492 (2020).

49. Sharma, A. M. & Kushner, R. F. A proposed clinical staging system for obesity. *Int. J. Obes.* **33**, 289–295 (2009).

50. Acosta, A. *et al.* Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic. *Obesity* **29**, 662–671 (2021).

51. Trang, K. & Grant, S. F. A. Genetics and epigenetics in the obesity phenotyping scenario. *Rev. Endocr. Metab. Disord.* **24**, 775–793 (2023).

52. Preda, A., Carbone, F., Tirandi, A., Montecucco, F. & Liberale, L. Obesity phenotypes and cardiovascular risk: From pathophysiology to clinical management. *Rev. Endocr. Metab. Disord.* **24**, 901–919 (2023).

53. Portincasa, P. & Frühbeck, G. Phenotyping the obesities: reality or utopia? *Rev. Endocr. Metab. Disord.* **24**, 767–773 (2023).